JNJ 87801493
Alternative Names: JNJ-87801493Latest Information Update: 05 Feb 2026
At a glance
- Originator Janssen Research & Development
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 20 Jan 2026 Phase-I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in Turkey (SC) (NCT07308132)
- 20 Jan 2026 Janssen Research & Development initiates a phase I trial in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in Australia (SC) (NCT07308132)
- 07 Dec 2024 Pharmacodynamics data from preclinical studies in Non-Hodgkin's lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)